Renalytix Share Discussion Threads

[74tom] 15/10/2020 23:09

Yep I’ve given up on it - Wan posted a piece further up the thread from the FDA a few weeks back, apparently they stopped issuing EUA’s for antibody testing, got to be a full application instead. I’m sure they are as frustrated as anyone given the amount of work that seemed to go into the submission. Fortunately, the collab with AZN / FDA filing of KidneyIntelX / commercial launch has happened in the meantime, so the ex Kantaro fundamentals have strengthened.

[mr roper] 15/10/2020 22:28

Not worth worrying about imho. Sideshow compared to the kidney tech.

[digger18] 15/10/2020 21:52

Still no news on the Kantaro/ Mount Sinai antibody test? Their website still says it will be available end of August! Something has not gone well with this and the lack of news is deafening.

[mr roper] 14/10/2020 16:22

Interesting. Hopefully some good news on the way

[mginvestor] 14/10/2020 16:00

I hadn't seen this. It's from August but Renalytix just tweeted it now.

Interesting points raised so worth a read.


"Investigative teams expected to participate in the study include experts from Mount Sinai, Yale, University of Michigan, Johns Hopkins and Rutgers.

Initial research findings are expected to be reported in late 2020." #RENX $RNLX


@mginvestor

[faz] 13/10/2020 22:18

I suggest you register with Verici for more info. Might depend on when you became a share holder as to whether you got an email. But any qualifying shareholders will get the opportunity to buy shares in the placement of those shares; what is not clear (to me) is when.

[74tom] 13/10/2020 16:17

Nope, didn't receive the email but saw the RNS.

Have had a quick scan through the Verici draft admission doc & main points of interest are;

- page 46 which details the use of proceeds - they are raising £12m gross
- page 30 which compares the sensitivity & specificity of the Verici tests vs competitors, showing them to be significantly better than the competition.

It also appears there is going to be a consolidation of the 59m shares granted in the dividend in specie - all details TBC.

[faz] 13/10/2020 15:56

Anyone else receive a mail from Verici just now? Verici Dx plc

(“Verici Dx” or the “Company”;) Intention to admit to trading on AIM

[mr roper] 10/10/2020 11:06

$rnlx had a decent intraday reversal on above average vol. Gut tells me we may get some sort of news next week. I'm expecting it to trend back to ipo price

[74tom] 09/10/2020 22:39

Thanks for the heads up on that Wan, good to be in the know. Ultimately Kantaro was a side show to KidenyIntelX & they’ve been executing on that. Going forwards id like to think they would learn from their communication errors here. Once you commit to a new project the market has every right to expect to be informed via RNS rather than relying on Bio-Techne results calls / Mount Sinai news releases / Tweets to try and understand what’s happening.

Positively, NASDAQ has stabilised over the last couple of weeks & rose on above average volume this evening which makes a change. I feel FDA approval will kick things off properly, let’s hope we get it this side of Christmas.

@Nimbo, hope your order got filled today - up another 7% I see! Is there anything specific fuelling the rise?

[digger18] 09/10/2020 18:34

The silence on the partnership is deafening! Launch originally planned for end of July, then August, then silence!
Very poor communication IMHO

[wan] 09/10/2020 15:16

74tom...Duly noted.

I also note in other developments, the FDA have upended the EUA's for LDT's. So, I am wondering if there needs to be a change in what is submitted by Mount Sinai/Kantaro i.e. to transition from EUA to a de novo pre-market approval or 510(k) cleared pathways, hence the delay?

See the following news coverage -

FDA Will No Longer Review EUA Submissions for SARS-CoV-2 Lab-Developed Tests
Oct 07, 2020


FDA takes hands off EUA review for COVID-19 lab developed tests

Dive Brief:
FDA has decided it will no longer review emergency use authorization submissions for COVID-19 laboratory developed tests to "make the best use" of agency resources and in the interests of public health.


Clearly though with the goal of producing more than ten million patient tests per month, the test still requires some sort of FDA clearance, as this fits the FDA guidance of a widely distributed test. "FDA continues to prioritize review of EUA requests for POC tests, home collection tests, at-home tests, tests that reduce reliance on test supplies, and high-throughput, widely distributed tests." (see first question under General FAQs -

So, the FDA will now be able to direct resources more effectively to tests that really make a difference, and arguably the Kantaro test fits this description (as well as the FDA description/guidance above).

Either way, and given the delay, it would be good to get some clarification.

[nimbo1] 09/10/2020 14:36

74tom yesterday I tried to buy some shares on nasdaq - put in an order for 4000 at 11.70 and the price spiked 7%! just shows how illiquid they are there too... only got given 100 and will have another bite at perhaps today.

[74tom] 09/10/2020 08:47

The quiet period continues, but I believe we'll see the finals in the next 10 days (to align with the NASDAQ listing date of 17/07 & provide quarterly financials).

By the way @Wan, I have been watching CareDX the last couple of weeks as they continue their ascent. Sadly I'm not a holder, but it bodes extremely well for the commerical path of RENX & Verici to see them go from strength to strength.

They closed last night at $50.5 for a market cap of $2.5b, three years ago they had a share price around $3 and market cap of $100m or so. They are still loss making as well, so it just shows what can be achieved by executing & scaling revenues!

[74tom] 05/10/2020 13:25

Thanks for sharing Homebrew, very interesting to listen to their views on both the now & future, Amati are a quality outfit.

[nimbo1] 05/10/2020 12:09

A decent interview thanks

[wan] 05/10/2020 10:46

Thanks again for the heads-up Homebrew. Renalytix gets more than a cursory mention during that podcast.

[wan] 05/10/2020 10:24

Thanks Homebrew.

[hpcg] 05/10/2020 10:12

link in 502 works as intended for me, thanks homebrew.

[wan] 05/10/2020 09:36

Homebrew...ADVFN not showing the link - Tinyulr.com

[wan] 05/10/2020 09:35

Homebrew...Thanks for the heads-up. If you cut and paste that link into Tinyulr.com it will shorten it, then paste it back in here and it will restore the thread width.

[homebrewruss] 05/10/2020 09:25

RENX discussed on the moneyweek podcast, nothing much new for existing holders but Gareth Blades of Amati global investors pics it as his favourite stock to hold for 10 years:

edit: wan, now shortened, I had to use a different shortener

[wan] 05/10/2020 08:31

Unfortunately the CKD market is massive, and even a small penetration into this market represents a very large market. Renalytix collaboration with AstraZeneca says quite a lot about the technology and the potential though.

[toffeeman] 05/10/2020 08:14

Couple of articles in the Times today about CKD - first one (about app for CKD) potentially concerning?